Effect of angiotensin-II receptor blocker candesartan alone or in combination with aldoster-one antagonist spironolactone on diastolic function in patients with chronic heart failure and relatively no

2008 ◽  
Vol 7 ◽  
pp. 159-159
Author(s):  
F AGEEV ◽  
O SVIRIDA ◽  
A OVCHINNIKOV
Keyword(s):  
Heart Failure ◽  
Angiotensin Ii ◽  
Chronic Heart Failure ◽  
Diastolic Function ◽  
Receptor Blocker ◽  
Angiotensin Ii Receptor Blocker ◽  
Angiotensin Ii Receptor

scholarly journals Effect of Angiotensin II Receptor Blocker on Cardiac Autonomic Activity in Patients with Chronic Heart Failure

2015 ◽  
Vol 21 (10) ◽  
pp. S172
Author(s):  
Shohei Ishikawa ◽  
Takahisa Noma ◽  
Keiji Matsunaga ◽  
Kaoru Mantani ◽  
Wataru Takabatake ◽  
...  
Keyword(s):  
Heart Failure ◽  
Angiotensin Ii ◽  
Chronic Heart Failure ◽  
Receptor Blocker ◽  
Angiotensin Ii Receptor Blocker ◽  
Autonomic Activity ◽  
Angiotensin Ii Receptor ◽  
Cardiac Autonomic Activity

Abstract 180: Synergistic Salutary Effects of HMG-CoA Reductase Inhibitor and Angiotensin II Receptor Blocker on Load-induced Heart Failure

2014 ◽  
Vol 115 (suppl_1) ◽  
Author(s):  
Yasuhiro Maejima ◽  
Mitsuaki Isobe
Keyword(s):  
Heart Failure ◽  
Angiotensin Ii ◽  
Reductase Inhibitor ◽  
Neonatal Rat ◽  
Receptor Blocker ◽  
Angiotensin Ii Receptor Blocker ◽  
Angiotensin Ii Receptor ◽  
Hmg Coa Reductase ◽  
Hmg Coa Reductase Inhibitor ◽  
Coa Reductase

We have shown previously that combined HMG-CoA reductase inhibitor (statin) and angiotensin II receptor blocker (ARB) therapy significantly improves both symptoms and left ventricular (LV) function over time in patients with heart failure (HF) by a clinical study [ HF-COSTAR Trial]. We elucidated the mechanisms of combination therapy with the ARB (losartan, LOS) and long-acting and statin (simvastatin, SIM) for the treatment of load-induced heart failure. Salt-loaded Dahl salt-sensitive (DS) rats were treated with vehicle, LOS (5mg/kg/day), SIM (2mg/kg/day) and LOS + SIM for 16 weeks. LOS and SIM in combination improved LV dysfunction (ΔLV fractional shortening; LOS = 60%, SIM = 42%, LOS + SIM = 24%, p <0.05), limited LV hypertrophy (ΔLV septal thickness; LOS = −21%, SIM = −18%, LOS + SIM = −13%, p <0.05) and reduced cardiac fibrosis (ΔLV collagen density; LOS = −26%, SIM = −16%, LOS + SIM = −28%, p <0.05) more than LOS or SIM alone. Both Rho and matrix metalloprotease-9 (MMP-9) activity in LV tissue were increased in untreated DS rats, and LOS and SIM in combination decreased these changes more than did LOS and SIM monotherapies. We confirmed that the plasma level of Exp-3174 (E3174), a LOS metabolite and a potent inverse agonist of angiotensin II receptor type 1, was higher in rats treated with LOS and SIM in combination than in those treated with LOS alone (E3174/LOS ratio; LOS = 2.6 ± 0.3 vs. LOS + SIM = 3.2 ± 0.2, p <0.05). Next, to mimic the response of volume-overload heart failure in vitro , cultured neonatal rat cardiomyocytes (CMs) were cyclically stretched. Stretch-induced increased CM hypertrophy was suppressed by pretreatment with both SIM and E3174 more than by pretreatment with LOS, E3174, SIM, or LOS and SIM in combination. Mechanical stretch also induced activation of extracellular signal regulated kinase (ERK) and the stretch-induced ERK activation of CMs was also significantly suppressed by SIM + E3174. In conclusion, LOS and SIM had beneficial myocardial effects in rats with salt-sensitive hypertension, partly through promoting the accumulation of plasma E3174. SIM enhanced the myocardial protective effects of LOS through suppression of Rho and MMP-9 activity. Thus, a combination of ARB with statin has a promising potential as a therapeutic strategy for HF.

scholarly journals Synergistic effects of HMG ‐CoA reductase inhibitor and angiotensin II receptor blocker on load‐induced heart failure

FEBS Open Bio ◽  
2018 ◽  
Vol 8 (5) ◽  
pp. 799-816 ◽  
Author(s):  
Yusuke Ito ◽  
Yasuhiro Maejima ◽  
Natsuko Tamura ◽  
Yuka Shiheido‐Watanabe ◽  
Masanori Konishi ◽  
...  
Keyword(s):  
Heart Failure ◽  
Angiotensin Ii ◽  
Reductase Inhibitor ◽  
Synergistic Effects ◽  
Receptor Blocker ◽  
Angiotensin Ii Receptor Blocker ◽  
Angiotensin Ii Receptor ◽  
Hmg Coa Reductase ◽  
Hmg Coa Reductase Inhibitor ◽  
Coa Reductase

Angiotensin II receptor blocker improves cardiac response to exercise in patients with non-ischemic heart failure

2004 ◽  
Vol 10 (5) ◽  
pp. S186
Author(s):  
Junji Sakata ◽  
Osato Kazuo ◽  
Murakami Tatsuaki ◽  
Moriuchi Ikuo ◽  
Shimada Yoshifumi ◽  
...  
Keyword(s):  
Heart Failure ◽  
Angiotensin Ii ◽  
Ischemic Heart ◽  
Cardiac Response ◽  
Receptor Blocker ◽  
Angiotensin Ii Receptor Blocker ◽  
Ischemic Heart Failure ◽  
Angiotensin Ii Receptor ◽  
Response To Exercise

scholarly journals Conflicting Perspectives on the Value of Neprilysin Inhibition in Heart Failure Revealed During Development of a Decision Aid Focusing on Patient Costs for Sacubitril/Valsartan

2020 ◽  
Vol 13 (9) ◽  
Author(s):  
Grace E. Venechuk ◽  
Larry A. Allen ◽  
Katherine Doermann Byrd ◽  
Neal Dickert ◽  
Daniel D. Matlock
Keyword(s):  
Heart Failure ◽  
Angiotensin Ii ◽  
Decision Aid ◽  
Enzyme Inhibitor ◽  
Receptor Blocker ◽  
Medical Decision ◽  
Angiotensin Ii Receptor Blocker ◽  
Angiotensin Ii Receptor ◽  
Heart Failure Medication ◽  
Neprilysin Inhibitor

Background: Despite concerns about rising costs in health care, cost is rarely an issue discussed by patients and clinicians when making treatment decisions in a clinical setting. This study aimed to understand stakeholder perspectives on a patient decision aid (PtDA) meant to help patients with heart failure choose between a generic and relatively low-cost heart failure medication (ACE [angiotensin-converting enzyme] inhibitor or angiotensin II receptor blocker) and a newer, but more expensive, heart failure medication (angiotensin II receptor blocker neprilysin inhibitor). Methods and Results: Feedback on the PtDA was solicited from 26 stakeholders including patients, clinicians, and the manufacturer. Feedback was recorded and discussed among development team members until consensus regarding both the interpretation of the data and the appropriate changes to the PtDA was reached. Stakeholders found the PtDA sufficient in clarifying the different treatment options for heart failure. However, patients, physicians, and the manufacturer had different opinions on the importance of highlighting cost in a PtDA. Patients indicated issues of cost were crucial to the decision while physicians and manufacturers expressed that the cost issue was secondary and should be de-emphasized. Conclusions: The stratified perspectives on the role of cost in medical decision-making expressed by our participants underscore the importance and challenge of having clear, frank discussions during clinic visits about treatment cost and perceived value.

Sign in / Sign up

Export Citation Format

Share Document